These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30016989)

  • 21. Additional hepatic
    Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
    BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
    Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
    Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion.
    de Baere T; Arai Y; Lencioni R; Geschwind JF; Rilling W; Salem R; Matsui O; Soulen MC
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):334-43. PubMed ID: 26390875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study.
    Fiorentini G; Rossi S; Bonechi F; Vaira M; De Simone M; Dentico P; Bernardeschi P; Cantore M; Guadagni S
    J Chemother; 2004 Jun; 16(3):293-7. PubMed ID: 15330328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
    J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.
    Gupta S; Yao JC; Ahrar K; Wallace MJ; Morello FA; Madoff DC; Murthy R; Hicks ME; Ajani JA
    Cancer J; 2003; 9(4):261-7. PubMed ID: 12967136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards.
    Lucatelli P; Argirò R; De Rubeis G; Rocco B; Corradini SG; Corona M; Nardis PG; Saba L; Mennini G; Fiorentino F; Corsi A; Catalano C; Bezzi M
    J Vasc Interv Radiol; 2019 Mar; 30(3):305-313. PubMed ID: 30713031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Arterial embolization of hepatic metastases from neuroendocrine tumors].
    Libicher M; Bovenschulte H
    Radiologe; 2009 Mar; 49(3):233-41. PubMed ID: 19183927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
    Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
    J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and complications of treating neuroendocrine metastases, embolization versus chemoembolization.
    Hartnell GG
    J Vasc Interv Radiol; 1999; 10(10):1416-7. PubMed ID: 10584661
    [No Abstract]   [Full Text] [Related]  

  • 33. Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.
    Elf AK; Andersson M; Henrikson O; Jalnefjord O; Ljungberg M; Svensson J; Wängberg B; Johanson V
    World J Surg; 2018 Feb; 42(2):506-513. PubMed ID: 29167951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.
    Dong XD; Carr BI
    Med Oncol; 2011 Dec; 28 Suppl 1():S286-90. PubMed ID: 21107755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum pancreastatin levels predict response to hepatic artery chemoembolization and somatostatin analogue therapy in metastatic neuroendocrine tumors.
    Desai DC; O'Dorisio TM; Schirmer WJ; Jung SS; Khabiri H; Villanueva V; Martin EW
    Regul Pept; 2001 Jan; 96(3):113-7. PubMed ID: 11111016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic neuroendocrine metastases: chemo- or bland embolization?
    Pitt SC; Knuth J; Keily JM; McDermott JC; Weber SM; Chen H; Rilling WS; Quebbeman EJ; Agarwal DM; Pitt HA
    J Gastrointest Surg; 2008 Nov; 12(11):1951-60. PubMed ID: 18709512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.
    Bhagat N; Reyes DK; Lin M; Kamel I; Pawlik TM; Frangakis C; Geschwind JF
    Cardiovasc Intervent Radiol; 2013 Apr; 36(2):449-59. PubMed ID: 22722717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
    Kawai S; Tani M; Okamura J; Ogawa M; Ohashi Y; Monden M; Hayashi S; Inoue J; Kawarada Y; Kusano M; Kubo Y; Kuroda C; Sakata Y; Shimamura Y; Jinno K; Takahashi A; Takayasu K; Tamura K; Nagasue N; Nakanishi Y; Makino M; Masuzawa M; Yumoto Y; Mori T; Oda T
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.
    Recchia F; Passalacqua G; Filauri P; Doddi M; Boscarato P; Candeloro G; Necozione S; Desideri G; Rea S
    Oncol Rep; 2012 May; 27(5):1377-83. PubMed ID: 22294036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
    Osborne DA; Zervos EE; Strosberg J; Boe BA; Malafa M; Rosemurgy AS; Yeatman TJ; Carey L; Duhaine L; Kvols LK
    Ann Surg Oncol; 2006 Apr; 13(4):572-81. PubMed ID: 16511671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.